secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inari Medical, Inc. (—)
CIK:        0001531048
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001531048-24-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inari Medical Q1 revenue $143.2M (+23% YoY); raises FY2024 guidance, GAAP net loss widens to $24.2M
--------------------------------------------------------------------------------

- Revenue $143.2M, up 23.3% YoY; gross margin 86.8% (down from 88.2% prior year).
- GAAP operating loss $17.2M vs $5.3M loss in Q1 2023; net loss $24.2M ($0.42 loss per share).
- Non-GAAP operating loss $5.6M, excluding $6.3M contingent consideration, $2.8M acquisition costs, $2.5M amortization.
- Raises FY2024 revenue guidance to $592.5M-$602.5M (from $580M-$595M); expects sustained profitability in H1 2025.
- PEERLESS study on track for H2 2024; growth driven by commercial expansion and new products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/0001531048-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/nari-20240430.htm
  HTML page:      https://secwatch.observer/filing/0001531048-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer